Yescarta denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for yescarta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Yescarta Under Step Therapy — and Why That Denial Is Challengeable

Step-therapy (also called "fail-first") policies require patients to try one or more less expensive treatments before an insurer will cover the requested drug. Applied to Yescarta (axicabtagene ciloleucel), a CAR-T cell therapy approved for relapsed or refractory large B-cell lymphoma and related indications, a step-therapy denial typically means UnitedHealthcare's system did not register sufficient evidence that required prior lines of treatment were attempted and failed. In oncology, step therapy conflicts with established guideline sequencing and with the FDA-approved indication itself, which is specifically defined around prior treatment failure — creating a strong basis for appeal.

## Why This Is Appealable

Yescarta's FDA-approved indication is inherently defined by prior treatment failure. Requiring additional "steps" after those prior lines have already failed is clinically circular and potentially contradicts the label itself. NCCN and other oncology guideline bodies address CAR-T therapy within a specific line-of-therapy context. If the patient already meets the label's and the applicable guideline's prior-treatment criteria, the step-therapy requirement has — by definition — been satisfied. The appeal argument is that the clinical record already documents the required treatment history and that additional steps would expose the patient to unnecessary toxicity and delay with no clinical benefit.

## Federal Appeal Framework

• Internal appeal (ERISA §503 / ACA §2719): File a written internal appeal within the deadline in your denial letter. Employer-sponsored plans must provide a full-and-fair review.
• Step-therapy override: Many states have enacted step-therapy override laws that prohibit insurers from requiring prior steps when guideline-recommended therapy has already failed. Check whether your plan is subject to state insurance law or only federal ERISA, as this affects which override rights apply.
• External review: After internal denial, escalate to an independent IRO under ACA §2719. The IRO can overturn the step-therapy requirement if it conflicts with the FDA label or recognized guidelines. The standard window is up to four months; expedited review is available when delay is clinically dangerous.

## Documentation to Gather

1. Diagnosis and staging records — pathology, molecular markers, and imaging confirming the specific relapsed/refractory diagnosis. 2. Complete prior-treatment history — for every prior line: the regimen name, start and end dates, best response, and reason for discontinuation (progression, intolerance, or other). This is the single most important document. 3. Treating oncologist's letter — explicitly stating that the patient has completed the required prior lines per the FDA label and applicable guideline, that those treatments failed, and that additional step-therapy would be medically inappropriate. 4. Performance status and disease trajectory — documenting why further delay increases risk of ineligibility for CAR-T (e.g., declining performance status). 5. UHC coverage policy — obtain the full text; match each step-therapy requirement against the documented prior-treatment history line by line.

## Criteria-Mapping Strategy

Pull the FDA-approved prescribing label for Yescarta and UnitedHealthcare's published coverage policy. List every prior-treatment requirement from both documents in a table. In the adjacent column, cite the exact chart note, infusion record, or oncology visit that documents completion of that requirement. Where the policy's steps are already embedded in the label's indication, state that explicitly. A well-constructed criteria map is the most persuasive document you can submit to both the internal reviewer and the IRO.